A Study to Assess the Safety, Tolerability and Pharmacokinetics of Lipovirtide in HIV-infected Patients

Phase 1

Completed

• Conditions: HIV Infections
• Interventions: Drug: Lipovirtide Injection

• Registration Number: NCT04592315
• Lead Sponsor: Shanxi Kangbao Biological Product Co., Ltd.

Brief Summary

To evaluate the safety, tolerability of single dose lipovirtide injection in HIV-infected individuals without prior antiviral treatment, and to investigate the pharmacokinetic characteristics of infected patients.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-09-30
• Study First Submitted QC: 2020-10-14
• Study First Posted: 2020-10-19
• Study Start: 2021-01-23
• Primary Completion: 2023-05-02
• Status Verified: 2023-06
• Study Completion: 2023-07-11
• Last Update Submitted: 2023-09-15
• Last Update Posted: 2023-09-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 46

Inclusion Criteria

1. Male or female aged from 18 to 60 (include 18 and 60)；
2. Body mass index (BMI) [weight (kg)/ height 2(m2)] is from 18.0 to 26.0（include 18.0 and 26.0），male weight≥50kg，female weight≥45kg；
3. Confirmed HIV-1 infection；
4. HIV viral load ≥ 1000 copies/mL；
5. Patients who have no birth plan within 2 weeks before the screening and 3 months after the end of the trial, consenting to take effective non-drug contraceptive measures during the trial period；
6. Understand the purpose of and procedures required for the study and having confirmed they are willing to participate in the study by signing the informed consent document.

Exclusion Criteria

1. Patients in the acute infection stage;
2. Confirmed AIDS patients；
3. Patients who have received antiviral therapy and/or have been vaccinated against HIV；
4. HBsAg is (+), and/or anti-HCV is (+)；
5. Abnormal liver function tests (ALT and / or AST> 3ULN, or total bilirubin> 2ULN)；
6. Glomerular filtration rate <70mL/min/1.73m2, or creatinine ≥ULN；
7. Patients who is currently suffering from a more serious chronic diseases, metabolic diseases (such as diabetes), neurological and mental diseases；
8. Patients who have previous history of pancreatitis；
9. Females who are pregnant or breastfeeding, or females of childbearing age who are unable to take contraception as required;
10. Allergic constitution or known allergy to the components of study drug；
11. With a history of smoking addiction within 12 months before screening (average number≥5 cigarettes per day)；
12. With a history of alcohol abuse within 12 months before screening (average drinking≥14 units of alcohol per week: 1 unit = 285mL beer, 25mL spirits, or 150mL wine) or those who have a positive alcohol breath test before enrollment；
13. With a history of drug abuse within 12 months before screening or those who tested positive for addictive substances before enrollment；
14. Patients who have participated in other investigational drug study within 3 months before screening (except for traditional Chinese medicine）；
15. Other factors that the investigators consider unsuitable for the trial.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
1	Lipovirtide Injection	Dose 5 mg
2	Lipovirtide Injection	Dose 10 mg
3	Lipovirtide Injection	Dose 20 mg
4	Lipovirtide Injection	Dose 40 mg
5	Lipovirtide Injection	Dose 60 mg
6	Lipovirtide Injection	Dose 80 mg

Primary Outcome Measures

Name	Time	Method
Pharmacokinetics：Cmax	Day 0 to Day 7	pharmacokinetic characteristics of Lipovirtide in infected patients：Cmax
Pharmacokinetics：AUC0-t	Day 0 to Day 7	pharmacokinetic characteristics of Lipovirtide in infected patients：AUC0-t

Trial Locations

Locations (1)

Beijing You'an Hospital, Beijing Medical University; 🇨🇳 Beijing, Beijing, China